Cergentis, based in Utrecht, the Netherlands, is a spin-off from the Royal Netherlands Academy of Arts and Sciences (KNAW) and its Hubrecht Institute for Developmental Biology & Stem Cell Research.
Cergentis’ Targeted Locus Amplification (TLA) Technology constitutes a paradigm shift in gene sequencing. The TLA Technology enables targeted complete sequencing of any locus/gene(s) of interest. TLA based sequencing will identify all hereditary and somatic genetic changes, including those found in complex samples such as tumours.
Cergentis’ mission is to contribute to the quality of genetic research and human healthcare by providing services and kits that enable the cost-effective complete sequencing of clinically relevant genes.